Jennison Associates LLC acquired a new position in shares of Rapport Therapeutics (NASDAQ:RAPP - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 62,287 shares of the company's stock, valued at approximately $1,105,000. Jennison Associates LLC owned about 0.17% of Rapport Therapeutics at the end of the most recent reporting period.
Several other hedge funds also recently modified their holdings of the stock. Values First Advisors Inc. acquired a new position in Rapport Therapeutics during the third quarter valued at approximately $31,000. BNP Paribas Financial Markets bought a new position in shares of Rapport Therapeutics in the third quarter valued at $34,000. JPMorgan Chase & Co. acquired a new position in Rapport Therapeutics during the third quarter worth $83,000. SG Americas Securities LLC bought a new stake in Rapport Therapeutics during the third quarter worth $101,000. Finally, MetLife Investment Management LLC bought a new stake in Rapport Therapeutics during the third quarter worth $117,000.
Rapport Therapeutics Stock Performance
Shares of RAPP traded up $0.30 during midday trading on Monday, reaching $16.43. The stock had a trading volume of 58,252 shares, compared to its average volume of 99,583. The firm has a 50 day simple moving average of $17.23 and a 200-day simple moving average of $20.31. Rapport Therapeutics has a one year low of $12.09 and a one year high of $29.74.
Rapport Therapeutics (NASDAQ:RAPP - Get Free Report) last posted its quarterly earnings results on Thursday, November 7th. The company reported ($0.50) EPS for the quarter, topping analysts' consensus estimates of ($0.57) by $0.07. As a group, equities analysts forecast that Rapport Therapeutics will post -3.65 earnings per share for the current year.
Rapport Therapeutics Company Profile
(
Free Report)
Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.
Further Reading
Before you consider Rapport Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Rapport Therapeutics wasn't on the list.
While Rapport Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
